Space oncology utilizes microgravity to study cancer biology, enabling faster tumor modelling and drug discovery. By forming 3D cell cultures in space, scientists develop superior treatments, like FDA-approved pembrolizumab, revolutionising global healthcare.
Why In News?
The Food and Drug Administration (FDA), USA, approved a 1-minute subcutaneous injection of the cancer drug pembrolizumab (Keytruda), developed using protein crystal growth research from the International Space Station (ISS).
What is Space Oncology?
Space oncology studies cancer biology and treatment development under microgravity conditions and cosmic radiation in space.
Objectives: Researchers aim to improve the understanding of cancer mechanisms, accelerate drug discovery, develop precision therapies, and advance biomedical innovation.
Protein Crystallization: Scientists enhance protein crystallization by removing gravitational sedimentation, which leads to highly uniform drug formulations.
Mechanobiological Responses: Researchers identify divergent responses to understand signalling pathways fundamental to metastasis and treatment resistance.
Key Features of Space Oncology Research
Microgravity Experiments: Space-grown proteins like the KRAS protein exhibit 50% more orderliness and a 5x better signal-to-noise ratio compared to Earth-grown crystals.
Tumour Organoid Studies: Scientists send living tumour organoids—derived from patients with glioblastoma, breast, and ovarian cancer—inside gas-permeable blood bags to study reactions to targeted therapies.
Drug Screening: Space serves as an accelerated testbed where experimental therapeutics like Rebecsinib are screened against space-grown organoids to evaluate antitumor activity.
Biotechnology Integration: Researchers utilize Ground-Based Facilities (GBFs) such as the Random Positioning Machine (RPM), 3D Clinostats, and Rotating Wall Vessels (RWV) to simulate microgravity on Earth.
International Collaboration: The Ax-4 mission integrates roughly 60 research activities representing 31 nations, pooling expertise from the USA, India, UAE, and Europe.
Genomic Analysis: Research utilizes transcriptomic and proteomic analyses to track how spaceflight alters gene expression, exosome release, and DNA methylation.
Immune Dysfunction: Studying natural immune suppression in space helps oncologists understand tumour-immune evasion and optimize immunotherapies.
Benefits of Space Oncology
Faster Drug Discovery: Researchers compress years of terrestrial cancer research into mere weeks by accelerating cellular growth and disease modeling.
Improved Treatments: Microgravity research transforms drug delivery, such as shifting pembrolizumab from a 2-hour intravenous infusion to a 1-minute subcutaneous injection.
Better Disease Modelling: Space-grown multicellular spheroids (MCS) replicate the hypoxic (low oxygen) core of solid tumors, serving as the ultimate in vitro model for testing hypoxia-targeting drugs.
Enhanced Precision Medicine: Microgravity uncovers variations in individual pharmacokinetics, paving the way for specialized space medications.
Biomedical Breakthroughs: Studies identify how space radiation induces carcinogenesis and oxidative stress, driving the development of biological countermeasures for radiation oncology.
Commercial Manufacturing: Orbital facilities like Commercial LEO Destinations (CLDs) will enable the mass production of highly stable, lower-viscosity biologics.
Source: THEHINDU
|
PRACTICE QUESTION Q. Regarding 'Space Oncology', consider the following statements: 1. It leverages microgravity to grow 3D multicellular spheroids which mimic human tumors better than 2D cultures on Earth. 2. The FDA recently approved a subcutaneous formulation of Pembrolizumab developed through protein crystallization on the International Space Station. 3. The Outer Space Treaty of 1967 provides comprehensive and explicit ethical guidelines for conducting commercial cancer clinical trials in space. Which of the statements given above are correct? A) 1 and 2 only B) 2 and 3 only C) 1 and 3 only D) 1, 2 and 3 Answer: A Explanation: Statement 1 is correct: Research confirms that microgravity conditions facilitate the spontaneous formation of 3D multicellular spheroids. These 3D models more accurately mimic the physiological environment and drug resistance of human tumors compared to traditional 2D cultures grown on Earth. Statement 2 is correct: The FDA approved a subcutaneous formulation of Pembrolizumab (Keytruda) in September 2025. This formulation's development was directly supported by protein crystallization experiments conducted on the International Space Station (ISS), which produced more uniform crystals suitable for high-concentration injectable suspensions. Statement 3 is incorrect: The Outer Space Treaty of 1967 focuses primarily on preventing the weaponization of space, prohibiting national appropriation, and establishing liability for space activities. It does not provide comprehensive or explicit ethical guidelines for conducting commercial cancer clinical trials; such activities would fall under national medical regulations (like the FDA) and international bioethical standards (like the Declaration of Helsinki), rather than the 1967 space treaty. |
Space oncology is a novel interdisciplinary field studying cancer cell biology, tumour progression, and pharmaceutical drug development under the unique conditions of microgravity and cosmic radiation in outer space.
Microgravity drastically alters cancer cells by reorganizing their cytoskeleton, changing gene expression, and causing them to spontaneously form 3D multicellular spheroids (MCS). These changes can slow down aggressive division, alter drug uptake, and provide a superior model for mimicking human tumours.
. Space research eliminates gravitational sedimentation, allowing for the creation of perfectly uniform protein crystals and highly concentrated biologics. This has already led to the FDA approval of faster, subcutaneous injections for immunotherapy drugs like pembrolizumab, alongside discovering new therapeutic targets like TMBIM6.
India is a major space-tech power. Through ISRO's Gaganyaan Programme and the Axiom-4 mission, Indian scientists are sending microgravity experiments (such as studying cancer growth and muscle regeneration) to the ISS. The planned Bharatiya Antariksh Station by 2035 will provide a permanent indigenous platform for pharmaceutical manufacturing and biomedical research.
© 2026 iasgyan. All right reserved
